|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
PL2726511T3
(pl)
|
2011-07-01 |
2019-12-31 |
Ngm Biopharmaceuticals, Inc. |
Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
|
|
US9611267B2
(en)
|
2012-06-13 |
2017-04-04 |
Incyte Holdings Corporation |
Substituted tricyclic compounds as FGFR inhibitors
|
|
DK2872491T3
(da)
*
|
2012-07-11 |
2021-08-09 |
Blueprint Medicines Corp |
Inhibitorer af fibroblastvækstfaktorreceptoren
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
EP3798228A1
(en)
|
2012-11-28 |
2021-03-31 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
SG11201504815QA
(en)
|
2012-12-27 |
2015-07-30 |
Ngm Biopharmaceuticals Inc |
Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
AR094812A1
(es)
|
2013-02-20 |
2015-08-26 |
Eisai R&D Man Co Ltd |
Derivado de piridina monocíclico como inhibidor del fgfr
|
|
US9321786B2
(en)
|
2013-03-15 |
2016-04-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
WO2014160521A1
(en)
|
2013-03-15 |
2014-10-02 |
Blueprint Medicines Corporation |
Piperazine derivatives and their use as kit modulators
|
|
EP3943087A1
(en)
|
2013-03-15 |
2022-01-26 |
Celgene CAR LLC |
Heteroaryl compounds and uses thereof
|
|
TWI649318B
(zh)
|
2013-04-19 |
2019-02-01 |
英塞特控股公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2015006492A1
(en)
|
2013-07-09 |
2015-01-15 |
Dana-Farber Cancer Institute, Inc. |
Kinase inhibitors for the treatment of disease
|
|
NZ718190A
(en)
|
2013-08-23 |
2017-10-27 |
Neupharma Inc |
Substituted quinazolines for inhibiting kinase activity
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
PT3409674T
(pt)
|
2013-10-17 |
2022-07-18 |
Blueprint Medicines Corp |
Processo para preparar composições úteis para tratar distúrbios relacionados com kit
|
|
LT3057943T
(lt)
|
2013-10-18 |
2018-11-12 |
Eisai R&D Management Co., Ltd. |
Pirimidino fgfr4 slopikliai
|
|
PE20160546A1
(es)
|
2013-10-25 |
2016-05-26 |
Novartis Ag |
Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4
|
|
BR112016008849B8
(pt)
|
2013-10-25 |
2022-09-06 |
Blueprint Medicines Corp |
Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
|
|
NZ718962A
(en)
|
2013-10-28 |
2019-12-20 |
Ngm Biopharmaceuticals Inc |
Cancer models and associated methods
|
|
US9695165B2
(en)
*
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
US9828363B2
(en)
|
2014-01-20 |
2017-11-28 |
Cleave Biosciences, Inc. |
Fused pyrimidines as inhibitors of P97 complex
|
|
AU2015209131B2
(en)
|
2014-01-24 |
2020-06-25 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
US9815834B2
(en)
*
|
2014-02-07 |
2017-11-14 |
Principia Biopharma, Inc. |
Quinolone derivatives as fibroblast growth factor receptor inhibitors
|
|
US9932329B2
(en)
|
2014-03-03 |
2018-04-03 |
Principia Biopharma, Inc. |
Benzimidazole derivatives as RLK and ITK inhibitors
|
|
MA38393B1
(fr)
*
|
2014-03-13 |
2018-11-30 |
Sanofi Sa |
Composés hétéroaryle et utilisations associées
|
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
|
EP3155005A4
(en)
|
2014-06-16 |
2018-07-11 |
NGM Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
CN105017227B
(zh)
*
|
2014-07-08 |
2018-03-09 |
四川百利药业有限责任公司 |
N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物
|
|
BR112017002268B1
(pt)
|
2014-08-18 |
2022-11-08 |
Eisai R&D Management Co., Ltd |
Sal de derivado de piridina monocíclica e cristal do mesmo
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
JP6585167B2
(ja)
|
2014-10-03 |
2019-10-02 |
ノバルティス アーゲー |
Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CN114129709A
(zh)
|
2014-10-23 |
2022-03-04 |
恩格姆生物制药公司 |
包含肽变异体的药物组合物及其使用方法
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
WO2016115412A1
(en)
|
2015-01-18 |
2016-07-21 |
Newave Pharmaceutical Llc |
Dual-warhead covalent inhibitors of fgfr-4
|
|
WO2016127074A1
(en)
|
2015-02-06 |
2016-08-11 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
|
|
EP3270694A4
(en)
*
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
MA41551A
(fr)
*
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
AU2016219822B2
(en)
*
|
2015-02-20 |
2020-07-09 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
RU2712222C2
(ru)
|
2015-03-25 |
2020-01-27 |
Нэшнл Кэнсер Сентер |
Терапевтическое средство против рака желчных протоков
|
|
US10189813B2
(en)
|
2015-03-25 |
2019-01-29 |
Novartis Ag |
Formylated N-heterocyclic derivatives as FGFR4 inhibitors
|
|
US9802917B2
(en)
|
2015-03-25 |
2017-10-31 |
Novartis Ag |
Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
|
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
|
WO2016168331A1
(en)
|
2015-04-14 |
2016-10-20 |
Eisai R&D Management Co., Ltd. |
Crystalline fgfr4 inhibitor compound and uses thereof
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
US10538517B2
(en)
|
2015-05-22 |
2020-01-21 |
Principia Biopharma, Inc. |
Quinolone derivatives as FGFR inhibitors
|
|
EP4112618A1
(en)
|
2015-06-03 |
2023-01-04 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
PT3322706T
(pt)
|
2015-07-16 |
2021-03-08 |
Array Biopharma Inc |
Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
RU2018106483A
(ru)
|
2015-07-24 |
2019-08-26 |
Блюпринт Медсинс Корпорейшн |
Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr
|
|
WO2017019957A2
(en)
|
2015-07-29 |
2017-02-02 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
KR102183356B1
(ko)
|
2015-08-11 |
2020-11-27 |
프린시피아 바이오파마, 인코퍼레이티드 |
Fgfr 억제제를 제조하기 위한 방법
|
|
BR112018003588A2
(pt)
|
2015-08-26 |
2018-09-25 |
Blueprint Medicines Corp |
compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3365335B1
(en)
*
|
2015-10-23 |
2024-02-14 |
Array Biopharma, Inc. |
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
|
|
TN2019000271A1
(en)
|
2015-10-26 |
2021-01-07 |
Univ Colorado Regents |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
|
EP3371171B1
(en)
|
2015-11-02 |
2023-10-25 |
Blueprint Medicines Corporation |
Inhibitors of ret
|
|
CA3003616C
(en)
|
2015-11-09 |
2020-07-28 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
|
US10414757B2
(en)
|
2015-11-16 |
2019-09-17 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
|
RU2018122089A
(ru)
|
2015-11-19 |
2019-12-25 |
Блюпринт Медсинс Корпорейшн |
Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk
|
|
WO2017104739A1
(ja)
|
2015-12-17 |
2017-06-22 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
乳がん治療剤
|
|
CN105669566A
(zh)
*
|
2016-03-09 |
2016-06-15 |
华东师范大学 |
一种医药中间体n-芳基喹唑啉-2-胺化合物的制备方法
|
|
WO2017161269A1
(en)
|
2016-03-17 |
2017-09-21 |
Blueprint Medicines Corporation |
Inhibitors of ret receptor tyrosine kinases
|
|
TN2019000332A1
(en)
|
2016-04-04 |
2021-05-07 |
Loxo Oncology Inc |
Methods of treating pediatric cancers
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
IL304018A
(en)
|
2016-04-04 |
2023-08-01 |
Loxo Oncology Inc |
Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
|
|
FI3442977T3
(fi)
|
2016-04-15 |
2023-09-26 |
Blueprint Medicines Corp |
Aktiviinireseptorin kaltaisen kinaasin estäjät
|
|
JP7372740B2
(ja)
|
2016-05-10 |
2023-11-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
|
|
ES2952056T3
(es)
|
2016-05-18 |
2023-10-26 |
Loxo Oncology Inc |
Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
|
|
KR20180002053A
(ko)
*
|
2016-06-28 |
2018-01-05 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
WO2018004258A1
(ko)
*
|
2016-06-28 |
2018-01-04 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US10227329B2
(en)
|
2016-07-22 |
2019-03-12 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
US10035789B2
(en)
|
2016-07-27 |
2018-07-31 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
AU2017312561B2
(en)
|
2016-08-15 |
2022-06-30 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
CA3034399A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
AU2017317864B2
(en)
|
2016-09-01 |
2020-01-16 |
Transthera Sciences (Nanjing), Inc. |
Inhibitors of fibroblast growth factor receptor and use thereof
|
|
WO2018049233A1
(en)
|
2016-09-08 |
2018-03-15 |
Nicolas Stransky |
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
|
|
WO2018055503A1
(en)
|
2016-09-20 |
2018-03-29 |
Novartis Ag |
Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
JOP20190077A1
(ar)
|
2016-10-10 |
2019-04-09 |
Array Biopharma Inc |
مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
WO2018072707A1
(zh)
*
|
2016-10-18 |
2018-04-26 |
保诺科技（北京）有限公司 |
芳香族醚类衍生物、其制备方法及其在医药上的应用
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
KR102362648B1
(ko)
|
2016-11-02 |
2022-02-11 |
노파르티스 아게 |
Fgfr4 억제제 및 담즙산 격리제의 조합물
|
|
WO2018090973A1
(zh)
*
|
2016-11-17 |
2018-05-24 |
广东众生药业股份有限公司 |
Fgfr4抑制剂及其制备方法和应用
|
|
KR101812266B1
(ko)
|
2016-11-25 |
2017-12-27 |
한국과학기술연구원 |
4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용
|
|
CN109661394B
(zh)
*
|
2016-12-19 |
2020-07-14 |
上海和誉生物医药科技有限公司 |
Fgfr4抑制剂、其制备方法与药学上的应用
|
|
CN108239069B
(zh)
*
|
2016-12-26 |
2021-01-05 |
南京药捷安康生物科技有限公司 |
一种用于成纤维细胞生长因子受体的抑制剂及其用途
|
|
CN108264511B
(zh)
*
|
2017-01-03 |
2021-04-13 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和其在医药上的用途
|
|
JP6888101B2
(ja)
|
2017-01-18 |
2021-06-16 |
アレイ バイオファーマ インコーポレイテッド |
ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
WO2018140600A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
CN108503593B
(zh)
*
|
2017-02-28 |
2021-04-27 |
暨南大学 |
2-氨基嘧啶类化合物及其应用
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
WO2018183712A1
(en)
|
2017-03-31 |
2018-10-04 |
Blueprint Medicines Corporation |
Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
|
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
AR111960A1
(es)
*
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
|
US11279697B2
(en)
|
2017-09-05 |
2022-03-22 |
Bioardis Llc |
Aromatic derivative, preparation method for same, and medical applications thereof
|
|
TWI791053B
(zh)
|
2017-10-10 |
2023-02-01 |
美商亞雷生物製藥股份有限公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
|
|
TWI876442B
(zh)
|
2017-10-10 |
2025-03-11 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
KR20190043437A
(ko)
|
2017-10-18 |
2019-04-26 |
씨제이헬스케어 주식회사 |
단백질 키나제 억제제로서의 헤테로고리 화합물
|
|
IL295978B2
(en)
|
2017-10-18 |
2024-01-01 |
Incyte Corp |
Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
|
|
EP3697786B1
(en)
|
2017-10-18 |
2022-08-31 |
Blueprint Medicines Corporation |
Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
|
|
CN109721600B
(zh)
*
|
2017-10-30 |
2021-04-27 |
上海凌达生物医药有限公司 |
一类含氮稠环化合物及其制备方法和用途
|
|
JP6997876B2
(ja)
|
2018-01-18 |
2022-02-04 |
アレイ バイオファーマ インコーポレイテッド |
Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
|
|
WO2019143977A1
(en)
|
2018-01-18 |
2019-07-25 |
Array Biopharma Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
|
WO2019143991A1
(en)
|
2018-01-18 |
2019-07-25 |
Array Biopharma Inc. |
SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
|
|
EP3750880B1
(en)
*
|
2018-02-08 |
2022-12-21 |
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. |
Pyrazine-2(1h)-ketone compound acting as fgfr inhibitor
|
|
BR112020017922A2
(pt)
|
2018-03-28 |
2020-12-22 |
Eisai R&D Management Co., Ltd. |
Agente terapêutico para carcinoma hepatocelular
|
|
BR112020020273A2
(pt)
|
2018-04-03 |
2021-04-06 |
Blueprint Medicines Corporation |
Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret
|
|
CN110386921A
(zh)
*
|
2018-04-23 |
2019-10-29 |
南京药捷安康生物科技有限公司 |
成纤维细胞生长因子受体抑制剂化合物
|
|
TW201946630A
(zh)
|
2018-05-04 |
2019-12-16 |
美商英塞特公司 |
Fgfr抑制劑之鹽
|
|
ES2991427T3
(es)
|
2018-05-04 |
2024-12-03 |
Incyte Corp |
Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
|
|
WO2019223766A1
(zh)
*
|
2018-05-25 |
2019-11-28 |
上海和誉生物医药科技有限公司 |
一种fgfr抑制剂、其制备方法和在药学上的应用
|
|
CN110577524B
(zh)
*
|
2018-06-07 |
2022-01-28 |
北京大学深圳研究生院 |
一种激酶选择性抑制剂
|
|
WO2019242689A1
(zh)
*
|
2018-06-22 |
2019-12-26 |
北京赛特明强医药科技有限公司 |
一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
|
|
JP7286755B2
(ja)
|
2018-07-31 |
2023-06-05 |
ロクソ オンコロジー， インコーポレイテッド |
（ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
|
|
CA3107168A1
(en)
|
2018-08-01 |
2020-02-06 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
CR20250050A
(es)
|
2018-09-05 |
2025-03-19 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
|
|
CA3111984A1
(en)
|
2018-09-10 |
2020-03-19 |
Array Biopharma Inc. |
Fused heterocyclic compounds as ret kinase inhibitors
|
|
AU2019338992B2
(en)
*
|
2018-09-14 |
2022-01-20 |
Abbisko Therapeutics Co., Ltd. |
FGFR inhibitor, preparation method therefor and application thereof
|
|
CN110950867A
(zh)
*
|
2018-09-27 |
2020-04-03 |
首药控股(北京)有限公司 |
一种fgfr4激酶抑制剂及其制备方法和用途
|
|
CN111138459B
(zh)
*
|
2018-11-06 |
2022-10-18 |
南京圣和药业股份有限公司 |
Fgfr4抑制剂的光学异构体及其应用
|
|
KR102195348B1
(ko)
|
2018-11-15 |
2020-12-24 |
에이치케이이노엔 주식회사 |
단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
|
|
WO2020119606A1
(en)
*
|
2018-12-10 |
2020-06-18 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of fibroblast growth factor receptor
|
|
CN113474337A
(zh)
|
2018-12-19 |
2021-10-01 |
奥瑞生物药品公司 |
作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
|
|
JP2022515198A
(ja)
*
|
2018-12-19 |
2022-02-17 |
アレイ バイオファーマ インコーポレイテッド |
ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
|
|
WO2020177067A1
(en)
*
|
2019-03-05 |
2020-09-10 |
Bioardis Llc |
Aromatic derivatives, preparation methods, and medical uses thereof
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
KR20210131369A
(ko)
*
|
2019-03-08 |
2021-11-02 |
쇼우야오 홀딩스 (베이징) 코., 엘티디. |
Fgfr4 키나아제 억제제 및 이의 제조 방법과 용도
|
|
SMT202300447T1
(it)
|
2019-04-12 |
2024-01-10 |
Blueprint Medicines Corp |
Forme cristalline di (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-yl)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-ammina e metodi di produzione
|
|
CN110317176A
(zh)
*
|
2019-07-04 |
2019-10-11 |
沈阳药科大学 |
2-氨基嘧啶类化合物及其用途
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN114072402B
(zh)
*
|
2019-07-26 |
2023-12-26 |
盛世泰科生物医药技术(苏州)股份有限公司 |
作为fgfr和vegfr双重抑制剂的吡啶衍生物
|
|
US11535609B2
(en)
|
2019-08-08 |
2022-12-27 |
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. |
Pyrazine-2(1H)-ketone compound preparation method
|
|
EP4011869B1
(en)
*
|
2019-08-08 |
2023-11-15 |
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. |
Crystal form d of pyrazine-2(1h)-ketone compound and preparation method therefor
|
|
US11603366B2
(en)
|
2019-08-08 |
2023-03-14 |
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. |
Crystalline form and B crystalline form of pyrazine-2(1H)-ketone compound and preparation method thereof
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
GEAP202415945A
(en)
|
2019-10-14 |
2024-04-25 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN112759593A
(zh)
|
2019-11-01 |
2021-05-07 |
北京伯汇生物技术有限公司 |
桥环并醛基吡啶衍生物及其应用
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
AU2020395185A1
(en)
|
2019-12-04 |
2022-06-02 |
Incyte Corporation |
Derivatives of an FGFR inhibitor
|
|
WO2021113492A1
(en)
|
2019-12-06 |
2021-06-10 |
Schrödinger, Inc. |
Cyclic compounds and methods of using same
|
|
AU2020414132B2
(en)
*
|
2019-12-23 |
2024-02-15 |
Beijing Scitech-Mq Pharmaceuticals Limited |
Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof
|
|
MX2022007171A
(es)
|
2019-12-27 |
2022-08-22 |
Schroedinger Inc |
Compuestos cíclicos y métodos de uso de estos.
|
|
WO2021146424A1
(en)
*
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP4157829A1
(en)
|
2020-05-29 |
2023-04-05 |
Blueprint Medicines Corporation |
Solid forms of pralsetinib
|
|
JP2023528880A
(ja)
*
|
2020-06-05 |
2023-07-06 |
キネート バイオファーマ インク． |
線維芽細胞増殖因子受容体キナーゼの阻害剤
|
|
CN116490507A
(zh)
|
2020-09-10 |
2023-07-25 |
薛定谔公司 |
用于治疗癌症的杂环包缩合cdc7激酶抑制剂
|
|
CN112851587A
(zh)
*
|
2021-01-21 |
2021-05-28 |
药雅科技(上海)有限公司 |
一种用于治疗癌症的炔类杂环化合物及其制备方法与用途
|
|
US20240148732A1
(en)
|
2021-01-26 |
2024-05-09 |
Schrödinger, Inc. |
Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
|
|
EP4286382A4
(en)
*
|
2021-01-26 |
2025-01-08 |
CGeneTech (Suzhou, China) Co., Ltd. |
CRYSTAL FORM OF A METHYLPYRAZOLE-SUBSTITUTED PYRIDOIMIDAZOLE COMPOUND AND METHOD FOR PREPARING THE SAME
|
|
CN114853740B
(zh)
*
|
2021-02-03 |
2023-08-01 |
药雅科技(上海)有限公司 |
炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途
|
|
IL304886B2
(en)
*
|
2021-03-04 |
2025-08-01 |
Lilly Co Eli |
Fgfr3 inhibitor compounds
|
|
WO2022194160A1
(zh)
*
|
2021-03-16 |
2022-09-22 |
上海启晟合研医药科技有限公司 |
非索替尼固体形式及其制备方法
|
|
TW202300150A
(zh)
|
2021-03-18 |
2023-01-01 |
美商薛定諤公司 |
環狀化合物及其使用方法
|
|
WO2022199045A1
(zh)
*
|
2021-03-26 |
2022-09-29 |
杭州普洛药物研究院有限公司 |
双环杂环fgfr4抑制剂，包含其的药物组合物和制剂，及其应用
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
AR126101A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|
|
CN113912602B
(zh)
*
|
2021-10-14 |
2023-05-05 |
温州医科大学 |
一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途
|
|
CN121548581A
(zh)
*
|
2023-05-25 |
2026-02-17 |
魔法弹丸治疗 |
用于抑制蛋白激酶的新型化合物和包含该化合物的药物组合物
|
|
TWI896159B
(zh)
*
|
2023-06-09 |
2025-09-01 |
大陸商上海和譽生物醫藥科技有限公司 |
一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
WO2025059027A1
(en)
|
2023-09-11 |
2025-03-20 |
Schrödinger, Inc. |
Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
|